Yes, myelodysplastic syndromes (MDS) are a form of cancer. MDS is a group of blood cancers in which the bone marrow fails to produce healthy blood cells. While MDS was historically viewed as a “pre-leukemic” condition or simply a bone marrow failure disorder, the World Health Organization now classifies it firmly among cancers of the blood-forming system.
Why MDS Is Classified as Cancer
The confusion around whether MDS “counts” as cancer is understandable. For decades, the name itself, myelodysplastic syndromes, made it sound more like a collection of symptoms than a malignancy. That changed with the WHO’s 5th edition classification of blood cancers, published in 2022, which renamed the condition “myelodysplastic neoplasms.” The abbreviation stays the same (MDS), but the new name explicitly signals that this is a neoplastic disease, meaning it involves the uncontrolled growth of abnormal cells.
MDS meets the biological criteria for cancer. It starts with acquired genetic mutations in blood-forming stem cells in the bone marrow. These mutations give the abnormal cells a growth advantage: they renew themselves more aggressively, evade the immune system, resist normal cell death, and crowd out healthy blood cell production. The result is a clone of dysfunctional cells that behaves like other cancers, just in a way that primarily disrupts blood counts rather than forming a visible tumor.
How MDS Affects the Body
The defining problem in MDS is ineffective blood cell production. Your bone marrow is working, sometimes even overworking, but the cells it makes are abnormal and don’t function properly. This leads to low blood counts, called cytopenias, which can affect red blood cells, white blood cells, platelets, or all three. Low red blood cells cause fatigue, shortness of breath, and pallor. Low white blood cells increase infection risk. Low platelets lead to easy bruising and bleeding.
The severity varies enormously. Some people have mild anemia that barely affects daily life, while others have dangerously low counts across all cell types. The degree depends on which genetic mutations are driving the disease, how many cell lines are affected, and how much the abnormal clone has taken over the bone marrow.
The Line Between MDS and Leukemia
MDS can progress to acute myeloid leukemia (AML), a more aggressive blood cancer, and this is one of the main reasons it’s taken seriously as a malignancy. The key dividing line is the percentage of immature cells called blasts in the bone marrow. In MDS, blasts account for less than 20% of bone marrow cells. Once that number crosses 20%, the diagnosis shifts to AML.
Within MDS itself, blast percentage matters for risk assessment. Patients with 5% to 9% blasts have a higher-risk form than those with fewer blasts, and those with 10% to 19% blasts are at the greatest risk of transformation. Not everyone with MDS progresses to AML, but the risk is real enough that monitoring blast counts is a core part of ongoing care. In patients whose MDS stops responding to treatment, nearly half may develop AML within about 19 months.
Who Gets MDS
MDS primarily affects older adults. The median age at diagnosis in the United States is 76, and it’s more common in men than women. The global incidence rate is roughly 4 cases per 100,000 people per year. Because the population is aging, MDS diagnoses have been rising steadily over the past few decades. Prior chemotherapy or radiation for other cancers is a known risk factor, as is long-term exposure to certain industrial chemicals like benzene.
How Risk Is Measured
Doctors use a scoring system called the IPSS-R (Revised International Prognostic Scoring System) to categorize MDS into five risk groups: very low, low, intermediate, high, and very high. The score factors in blood counts, the percentage of blasts in the bone marrow, and specific chromosome abnormalities found in the cancer cells.
These categories translate into very different outlooks. Patients in the very low risk group have a median survival around 8.8 years. Low-risk patients average about 5.3 years, and intermediate-risk patients roughly 3 years, though outcomes within this middle group vary widely. Higher-risk categories carry shorter survival times and a greater chance of progressing to AML. Certain genetic mutations also shift the picture. Mutations in a gene called SF3B1, found in about half of MDS patients, are associated with a more favorable, slow-moving disease course. Other mutations carry a worse prognosis.
Treatment for Lower-Risk MDS
For people with lower-risk MDS, the goal is managing symptoms and maintaining quality of life rather than pursuing aggressive treatment. Many patients need regular red blood cell transfusions to manage anemia, and up to 40% of MDS patients become transfusion-dependent over time. Medications that stimulate red blood cell production can reduce transfusion needs for some patients.
One concern with ongoing transfusions is iron overload. Each unit of transfused blood delivers 200 to 250 milligrams of iron, roughly 100 times what you’d normally absorb in a day. Over months or years, this excess iron accumulates and can damage the liver and heart. Iron chelation therapy, which removes excess iron from the body, is sometimes recommended for lower-risk patients who’ve received 20 or more transfusion units, though the decision is made on a case-by-case basis.
Treatment for Higher-Risk MDS
For higher-risk MDS, treatment shifts toward slowing disease progression and delaying transformation to AML. The mainstay of therapy is a class of drugs called hypomethylating agents, which have been the standard since the early 2000s. These medications work by reversing abnormal chemical modifications on DNA that silence genes the cancer cells need turned off to keep growing. They’re typically given in monthly cycles, and an oral formulation was approved in 2020, making treatment more convenient than the traditional injections.
The only treatment that can cure MDS is a stem cell transplant from a donor. This replaces the diseased bone marrow with healthy donor cells. Transplant eligibility depends on overall fitness, the severity of other health conditions, and the aggressiveness of the MDS. Fit patients with higher-risk disease scores are the primary candidates. Patients with very advanced disease, significant health problems, or advanced age have a lower chance of cure with standard transplant and may be better served by other approaches. For those who do qualify, a transplant offers a real chance at long-term remission, but it carries serious risks including graft failure and complications from the donor immune cells.
Living With a Cancer That Doesn’t Always Feel Like One
Part of what makes MDS confusing for patients is the wide spectrum of severity. Someone with very low-risk MDS may live for a decade with minimal treatment, checking blood counts every few months and otherwise going about daily life. Someone with high-risk MDS faces a much more urgent situation, with frequent medical appointments, transfusions, and treatment decisions that resemble those of any serious cancer diagnosis. Both are living with the same disease category, but the day-to-day reality can look completely different.
Because MDS is now formally classified as a cancer, patients have access to oncology support services, clinical trials, and insurance coverage pathways that might not have been available under older, vaguer labels. If you’ve been diagnosed with MDS and told it’s “not really cancer” or “just a blood disorder,” the medical consensus has moved clearly in the other direction. It is a cancer of the bone marrow, and treating it that way leads to better monitoring, more treatment options, and clearer conversations about what to expect.